ALK and non-small cell lung carcinoma: Based on her progression-free survival of more than 18 months, we speculate that second generation ALK-TKIs such as ceritinib, given after crizotinib, may help prevent or delay brain metastasis and ALK-TKI resistance in ALK-positive NSCLC.